Vivos Therapeutics Inc. (NASDAQ:VVOS) shares fell 6.5% in pre-market trading on Monday after the medical device company reported second-quarter revenue below Wall Street expectations, despite delivering a smaller-than-anticipated adjusted loss.
Revenue for the quarter reached $5.15 million, missing the analyst consensus estimate of $5.57 million. Adjusted loss per share came in at -$0.31, however, outperforming expectations for a loss of -$0.37 per share.
Revenue climbs 35% as Nevada services expand
Despite falling short of forecasts, second-quarter revenue increased 35% from $3.8 million in the corresponding period of 2025.
The improvement was driven primarily by service revenue generated from sleep testing and treatment services within the company’s Nevada operations.
Growth was even stronger across the first half of the year. Revenue for the six months ended June 30, 2026 reached $10.3 million, representing a 51% increase from $6.8 million in the same period a year earlier.
Vivos also recorded an improvement in profitability at the gross level. Second-quarter gross margin increased to 57% from 55% a year earlier.
Operating losses showed little movement, remaining at $4.9 million compared with the second quarter of 2025.
Vivos sees Q2 as key point in growth strategy
Chairman and Chief Executive Officer Kirk Huntsman highlighted the company’s efforts to establish a stronger platform for future expansion.
“The second quarter of 2026 represented a watershed moment in the history of Vivos as we continued to lay the foundation for potential significant revenue enhancement and growth for the remainder of 2026 and beyond,” said Huntsman.
The year-on-year increase in revenue and improvement in gross margin provide evidence of operational progress, although the continuing operating loss indicates that further growth will be required to strengthen the company’s overall profitability.
Cash position declines as equity deficit widens
Vivos ended June with cash and cash equivalents of $1.8 million, compared with $2.0 million at the end of 2025.
Stockholders’ equity remained negative and deteriorated during the first half, with the deficit widening to $3.8 million as of June 30 from $1.5 million at December 31, 2025.
The combination of continued operating losses, a relatively limited cash balance and a larger equity deficit leaves the company’s financial position an important area for investors to monitor alongside its revenue growth.
No specific financial guidance provided
Vivos did not issue specific financial guidance for the coming quarters.
That leaves investors focused on whether the strong year-on-year revenue expansion can continue through the second half of 2026 and whether increased sales can translate into narrower operating losses and improved cash generation.
The initial market reaction remained negative, with the revenue miss outweighing the better-than-expected adjusted loss per share and improvement in gross margin.
Vivos Therapeutics stock price
